Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

Kobayashi, 1989, Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes, J Exp Med, 170, 827, 10.1084/jem.170.3.827 Gubler, 1991, Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor, Proc Natl Acad Sci USA, 88, 4143, 10.1073/pnas.88.10.4143 Gately, 1993, Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors, Cancer Invest, 11, 500, 10.3109/07357909309018881 Mehrotra, 1993, Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes, J Immunol, 151, 2444, 10.4049/jimmunol.151.5.2444 Manetti, 1993, Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells, J Exp Med, 177, 1199, 10.1084/jem.177.4.1199 Kennedy, 1994, Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones, Eur J Immunol, 24, 2271, 10.1002/eji.1830241002 Rosenzweig, 2005, Defects in the interferon-γ and interleukin-12 pathways, Immunol Rev, 203, 38, 10.1111/j.0105-2896.2005.00227.x Brunda, 1993, Antitumor and antimetastatic activity of interleukin 12 against murine tumors, J Exp Med, 178, 1223, 10.1084/jem.178.4.1223 Tahara, 1996, Murine models of cancer cytokine gene therapy using interleukin-12, Ann N Y Acad Sci, 795, 275, 10.1111/j.1749-6632.1996.tb52677.x Colombo, 1996, Amount of interleukin 12 available at the tumor site is critical for tumor regression, Cancer Res, 56, 2531 Cavallo, 1999, Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12, Cancer Res, 59, 414 Cohen, 1995, IL-12 deaths: explanation and a puzzle, Science, 270, 908, 10.1126/science.270.5238.908a Leonard, 1997, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production, Blood, 90, 2541 Del Vecchio, 2007, Interleukin-12: biological properties and clinical application, Clin Cancer Res, 13, 4677, 10.1158/1078-0432.CCR-07-0776 Mahvi, 2007, Intratumoral injection of IL-12 plasmid DNA–results of a phase I/IB clinical trial, Cancer Gene Ther, 14, 717, 10.1038/sj.cgt.7701064 Kang, 2001, Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study, Hum Gene Ther, 12, 671, 10.1089/104303401300057388 Daud, 2008, Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma, J Clin Oncol, 26, 5896, 10.1200/JCO.2007.15.6794 Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, 23, 2346, 10.1200/JCO.2005.00.240 Dudley, 2008, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, J Clin Oncol, 26, 5233, 10.1200/JCO.2008.16.5449 Cohen, 2005, Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR, J Immunol, 175, 5799, 10.4049/jimmunol.175.9.5799 Hughes, 2005, Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions, Hum Gene Ther, 16, 457, 10.1089/hum.2005.16.457 Morgan, 2003, High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens, J Immunol, 171, 3287, 10.4049/jimmunol.171.6.3287 Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 Lieschke, 1997, Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo, Nat Biotechnol, 15, 35, 10.1038/nbt0197-35 Hooijberg, 2000, NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells, Blood, 96, 459, 10.1182/blood.V96.2.459 Karttunen, 1992, Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens, Proc Natl Acad Sci USA, 89, 6020, 10.1073/pnas.89.13.6020 Finkelstein, 2004, Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer, J Leukoc Biol, 76, 333, 10.1189/jlb.0304120 Overwijk, 2003, Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells, J Exp Med, 198, 569, 10.1084/jem.20030590 Kerkar, 2010, Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts, Cancer Res, 70, 6725, 10.1158/0008-5472.CAN-10-0735 Weiss, 2007, Immunotherapy of cancer by IL-12-based cytokine combinations, Expert Opin Biol Ther, 7, 1705, 10.1517/14712598.7.11.1705 Atkins, 1997, Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies, Clin Cancer Res, 3, 409 Car, 1999, The toxicology of interleukin-12: a review, Toxicol Pathol, 27, 58, 10.1177/019262339902700112 Coughlin, 1997, The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12, Cancer Res, 57, 2460 Gollob, 2001, Clinical use of systemic IL-12 therapy, Cancer Chemother Biol Response Modif, 19, 353 Fan, 2002, IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation, Cytokine, 19, 126, 10.1006/cyto.2002.1958 Lee, 2003, Inhibition of TCR-induced CD8 T cell death by IL-12: regulation of Fas ligand and cellular FLIP expression and caspase activation by IL-12, J Immunol, 170, 2456, 10.4049/jimmunol.170.5.2456 Estaquier, 1995, T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons, J Exp Med, 182, 1759, 10.1084/jem.182.6.1759 Wagner, 2004, A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells, Cancer Gene Ther, 11, 81, 10.1038/sj.cgt.7700664 Chen, 2008, A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs, Mol Ther, 16, 749, 10.1038/mt.2008.3 Gao, 2010, Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma, Cancer Lett, 290, 157, 10.1016/j.canlet.2009.08.031 Elzaouk, 2006, Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model, Exp Dermatol, 15, 865, 10.1111/j.1600-0625.2006.00479.x Smith-Garvin, 2009, T cell activation, Annu Rev Immunol, 27, 591, 10.1146/annurev.immunol.021908.132706 Eisenring, 2010, IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46, Nat Immunol, 11, 1030, 10.1038/ni.1947 Rosenberg, 2009, Adoptive cell therapy for the treatment of patients with metastatic melanoma, Curr Opin Immunol, 21, 233, 10.1016/j.coi.2009.03.002 Prieto, 2010, Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy, J Immunother, 33, 547, 10.1097/CJI.0b013e3181d367bd Besser, 2010, Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients, Clin Cancer Res, 16, 2646, 10.1158/1078-0432.CCR-10-0041 Dudley, 2010, CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma, Clin Cancer Res, 16, 6122, 10.1158/1078-0432.CCR-10-1297 Schambach, 2007, Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors, Mol Ther, 15, 1167, 10.1038/sj.mt.6300152 Wargo, 2009, Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression, Cancer Immunol Immunother, 58, 383, 10.1007/s00262-008-0562-x